Ontario’s Referral and Listing Criteria for Adult Simultaneous Kidney and Pancreas Transplantation

Version 2.0

Trillium Gift of Life Network
Adult Simultaneous Kidney and Pancreas Transplantation
Referral & Listing Criteria

PATIENT REFERRAL CRITERIA:
The patient referral criteria are guidelines which a Health Care Provider would utilize to refer a patient to a transplant center for assessment. Simultaneous kidney-pancreas transplantation should considered in end-stage renal failure patients with type 1 diabetes (based on absent c-peptide) and patients with type 2 diabetes who meet the following criteria: BMI <35; total insulin required < 1 unit/kg/day; insulin-dependence > 5 years, presence of secondary diabetes complications, and medical compliance. Simultaneous kidney-pancreas transplantation can also be considered in patients who have lost islet function from chronic pancreatitis, cystic fibrosis, and pancreatectomy.

PATIENT LISTING INDICATIONS:
Each patient is assessed individually for their suitability for transplantation by the transplant program. The criteria identified below are the agreed criteria for which a patient may be eligible to be waitlisted for simultaneous kidney-pancreas transplantation in Ontario.

1) **Diabetes**: Although the majority of patients considered for simultaneous kidney-pancreas transplantation have long-standing type 1 diabetes, excellent results can be achieved in well-selected patients with type 2 diabetes mellitus and in patients who have lost beta-cell function from pancreatectomy, chronic pancreatitis, and cystic fibrosis.

2) **Psychosocial Considerations**: Patients should be emotionally and psychologically stable to be considered for simultaneous kidney-pancreas transplantation. Patients should be non-smokers to be eligible for transplantation.

3) **Medical Stability**: Patients should be physically able to withstand surgery and immunosuppression to be eligible for transplantation.

4) **End Stage Renal Disease (ESRD)**: Listing for transplant may be considered for patients with ESRD listed by dialysis start date.

5) **Pancreatectomy**: Patients who have had a previous pancreatectomy may be considered for transplantation.
**ABSOLUTE LISTING CONTRAINDICATIONS:**

The following are conditions relating to the transplant candidate that constitute absolute contraindications to simultaneous kidney-pancreas transplantation. As such, they prevent a transplant from being done until the condition is resolved.

1) **Co-Morbidities:** Patients with any co-morbidity that decreases the likelihood of surviving 5 years post-transplant to below 50% or whom which the peri-operative risk is deemed unacceptably high, are not candidates for transplantation.

2) **Consent:** Patients who do not want a transplant should not be listed for transplantation.

3) **Post-Transplant Care:** Patients with an inadequate or unsafe post-transplant care plan are not candidates for transplantation.

4) **Psychosocial Considerations:** Patients who display social support/compliance issues that prohibit adherence to therapy (e.g. compliance with medications) are not candidates for transplantation. Transplantation should be delayed until patients have demonstrated adherence to therapy for at least 6 months. Smoking is an absolute contraindication to transplantation.

5) **Malignancy:** In general, patients with an active malignancy are not candidates for transplantation. Transplant candidates with a previous history of malignancy should be tumour-free before proceeding with transplantation. Specific contraindications include:

   1. **Breast Cancer:** Patients with advanced breast cancer (stage III or IV) should not undergo transplantation.
   2. **Liver Cancer:** Transplantation is generally not recommended for patients with liver cancer unless it is part of a treatment strategy that includes liver transplantation.
   3. **Active Multiple Myeloma:** Patients with active multiple myeloma should not undergo transplantation, although patients with myeloma who have had a successful stem cell transplant may be considered.
   4. **Prostate Cancer:** Patients with advanced disease (Gleason scale ≥ 7, T3c, T4, N+, M+) should not undergo transplantation.

Most transplant candidates with a history of malignancy should wait a period of time between successful treatment and transplantation. Patients who do not meet the following waiting period criteria are not eligible for transplantation.

   1. **Bladder Cancer:** Patients with bladder cancer must wait at least 2 years from successful treatment to transplantation, although superficial low-grade lesions may not require any waiting time.
   2. **Breast Cancer:** Patients with breast cancer must wait at least 5 years from successful treatment to transplantation. Patients with early in situ (e.g., ductal carcinoma in situ) lesions may only require a 2-year wait.
   3. **Cervical Cancer:** Patients with cervical cancer must wait at least 2 years from treatment to transplantation. Patients with in situ cervical lesions may proceed with transplantation before the 2 year wait period.
   4. **Colorectal Cancer:** Patients with colorectal cancer must wait at least 5 years from successful treatment to transplantation. A shorter waiting time of 2–5 years may be sufficient in patients with localized disease.
5. **Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, Post-Transplant Lymphoproliferative Disorder, or Leukemia:** Patients with these diseases must wait at least 2 years from successful treatment to transplantation.

6. **Lung Cancer:** Patients with lung cancer must wait at least 2 years from successful treatment to transplantation.

7. **Melanoma:** Patients with melanoma must wait at least 5 years from successful treatment to transplantation. Patients with in situ melanoma may be considered for transplantation after waiting at least 2 years.

8. **Basal Cell Carcinoma of the Skin:** Patients do not require any waiting time after successful removal before proceeding with transplantation.

9. **Squamous Cell Carcinoma of the Skin:** There is no firm recommendation on wait time.

10. **Prostate Cancer:** Patients with prostate cancer must wait at least 2 years from successful treatment to transplantation. Patients with focal, microscopic low-grade (Gleason's scale ≤ 6), low-risk (T1a, T1c) disease may not require any waiting period.

11. **Renal Cell Carcinoma:** Patients with renal cell carcinoma must wait at least 2 years from successful treatment to transplantation. Patients with small, incidental tumours may not require any waiting period. Patients with large or invasive or symptomatic tumours may require a waiting period of 5 yrs.

12. **Wilms’ Tumour:** Patients with Wilms’s Tumour must wait at least 1 year from successful treatment to transplantation.

13. **Testicular Cancer:** Patients with testicular cancer must wait at least 2 years from successful treatment to transplantation.

14. **Thyroid Cancer:** Patients with thyroid cancer must wait at least 2 years from successful treatment to transplantation.

6) **Pulmonary Disease:** Patients who require home oxygen therapy (Grade C), have uncontrolled asthma (Grade C), or have severe cor pulmonale are not candidates for transplantation. Patients with severe chronic obstructive pulmonary disease (COPD) – pulmonary fibrosis or restrictive disease with any of the following parameters are not candidates for transplantation:

- Best forced expiratory volume in 1 s (FEV1) < 25% predicted value;
- PO$_2$ room air < 60 mmHg with exercise desaturation, SaO$_2$ < 90%;
- > 4 lower respiratory infections in the last 12 months; or
- Moderate disease with evidence of progression.

7) **Cardiac Disease:** Patients with inoperable valve disease should not be considered for transplant. Patients with severe irreversible (non-uremic) cardiac dysfunction should not be listed for transplantation alone, but selected patients may be candidates for combined heart transplants.

All transplantation candidates should be assessed for the presence of ischemic heart disease (IHD) before transplantation. The minimum required investigations include medical history, physical examination, electrocardiogram (ECG) and a chest radiograph. Patients with IHD in the following situations are not eligible for transplantation:

- Patients with progressive symptoms of angina;
- Patients with a myocardial infarction within 6 months;
- Patients without an appropriate cardiac workup;
- Patients with severe diffuse disease, especially with positive non-invasive tests in whom intervention is not possible and in whom expected survival is sufficiently compromised so that transplantation is not reasonable.
8) **Peripheral Vascular Disease:** Patients with large uncorrectable abdominal aneurysms, severe occlusive common iliac disease, active gangrene or recent atheroembolic events are not candidates for transplantation.

9) **Gastrointestinal Disease:** Patients with the following conditions are not candidates for transplantation:
   - Acute pancreatitis within 6 months;
   - Active inflammatory bowel disease; or,
   - Active peptic ulcer disease until disease is successfully treated.

**RELATIVE LISTING CONTRAINDICATIONS:**

The following are conditions relating to the transplant candidate that constitute relative contraindications. While each patient is evaluated on an individual basis, the presence of one or more of the following will often preclude acceptance as a candidate for simultaneous kidney-pancreas transplantation.

1) **Age and functional capacity:** Generally patients over the age of 70 are not candidates for simultaneous kidney-pancreas transplantation.

   Cognitive or neurodevelopmental delay is not an absolute contraindication to simultaneous kidney-pancreas transplantation.

2) **Weight:** Generally, patients weighing less than 10kg should not undergo transplantation.

3) **Renal Function:** Patients with evidence of renal disease that have a high rate of recurrence and no effective therapy to prevent graft loss post-transplant may not be considered for transplantation.

4) **Psychosocial Considerations:** Cognitive impairment is not an absolute contraindication to transplantation. However, particular care must be taken to ensure that informed consent can be obtained and that a support system is in place to ensure adherence to therapy and patient safety. A history of psychiatric illness is not an absolute contraindication to transplantation. Capacity should be evaluated when indicated.

   Transplantation should be delayed until the patient has demonstrated freedom from substance abuse for at least 6 months.

5) **Obesity:** Referrals will be accepted on patients with a Body Mass Index (BMI) of <35 kg/m². Patients with a BMI >36 kg/m² will be evaluated on an individual basis by the surgical team.

6) **Systemic Diseases:** Systemic diseases leading to End Stage Renal Disease (ESRD) are usually not a contraindication to transplantation; however, the presence and severity of extra-renal disease will often determine whether transplantation is an option.

7) **Infections:** Patients with the following relative contraindications may not be eligible for transplantation:
   1. Patients with active infection, whether of viral, bacterial or fungal origin, may not be considered for transplant;
   2. Patients with chronic open infected wounds may not be appropriate for transplant listing.

Patients meeting the following criteria may be considered for transplant:
   1. Serostatus for cytomegalovirus and Epstein–Barr virus should be assessed before transplant but should not determine eligibility for transplantation;
2. All patients being assessed for transplantation should be screened for HIV infection. HIV-infected patients with end-stage kidney failure may be considered for transplantation if they meet the following criteria:
   - Demonstrated adherence to a highly active anti-retroviral therapy (HAART) regimen;
   - Undetectable (< 50 copies/mL) HIV viral load for > 3 months;
   - Cluster of differentiation (CD4) lymphocyte count > 200/mL for > 6 months;
   - No opportunistic infections;
   - Willingness to use prophylaxis against congenital cytomegalovirus infection (CMV), Herpes simplex virus, Pneumocystis carinii pneumonia and fungal infection;
   - Freedom from neoplasia, except for treated basal or squamous cell carcinoma of the skin, in situ anogenital carcinoma (human papilloma virus-associated anal intraepithelial neoplasia), solid tumours treated with curative therapy and disease-free at 5 years;
   - Kidney-pancreas transplantation eligibility criteria are met.

8) **Pulmonary Disease**: Patients with moderate chronic obstructive pulmonary disease (COPD) – pulmonary fibrosis or restrictive disease with any of the following parameters may not be considered for transplantation:
   - Best Tiffeneau-Pinelli index (FEV₁) 25–50% of predicted value;
   - Partial pressure of oxygen (PO₂) room air < 60–70 mmHg; or
   - Restrictive disease with exercise desaturation, SaO₂ 90%.

9) **Cardiac Disease**: All patients should be assessed for the presence of ischemic heart disease (IHD) before transplantation. The minimum required investigations include medical history, physical examination, electrocardiogram (ECG) and a chest radiograph. Patients with IHD should be eligible for transplantation if they fall into one of the following categories:
   - Low-risk asymptomatic patients;
   - Asymptomatic patients with negative non-invasive testing;
   - Patients who have undergone successful intervention; or
   - Patients who on angiography have non-critical disease and are on appropriate medical therapy.

Left ventricular (LV) dysfunction is not necessarily a contraindication to transplantation.

Uremic LV dysfunction may improve after transplantation; thus it is not necessarily a contraindication to wait listing.

10) **Cerebral Vascular Disease**: Transplantation should be deferred in patients with a history of stroke or transient ischemic attack for at least 6 months following the event. The patient should be stable, fully evaluated and treated with risk-reduction strategies before transplantation.

11) **Peripheral Vascular Disease**: The presence of pre-transplant peripheral vascular disease (PVD) is not an absolute contraindication to transplantation. However, the risk of death is increased and the presence of PVD should be considered in the context of other comorbidities in determining eligibility for transplantation.

12) **Gastrointestinal Disease**: The presence of asymptomatic cholelithiasis is not a contraindication to transplantation. Patients with chronic pancreatitis in remission for less than 1 year may not be eligible for transplantation.
13) **Liver Disease:** Patients who are hepatitis B surface antigen positive or hepatitis C antibody positive should be considered for transplantation. However, eligibility will depend on other considerations such as viral load and liver function and liver histology.

Transplant candidates with severe cirrhosis should not be considered for simultaneous kidney-pancreas transplantation, but may be considered for combined liver-kidney-pancreas transplantation.

14) **Genitourinary Disease:** A urologic cause of ESRD is not necessarily a contraindication to transplantation provided appropriate urinary tract drainage can be achieved. Transplantation is not contraindicated in patients with a dysfunctional bladder.

15) **Hematologic Disorders:** The presence of thrombophilia, hypercoagulable state or cytopenias is not an absolute contraindication to transplantation, but these conditions should be fully investigated.

16) **Hyperparathyroidism:** Hyperparathyroidism is not an absolute contraindication to transplantation, but should be fully investigated. Parathyroidectomy should be considered for those who have failed medical management or have severe, persistent complications of hyperparathyroidism.
## Version Control:

<table>
<thead>
<tr>
<th>Name of Document</th>
<th>Ontario’s Referral and Listing Criteria for Adult Simultaneous Kidney and Pancreas Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1.0</td>
<td>Created May 2011</td>
</tr>
<tr>
<td>Version 2.0</td>
<td>Updated April 2015</td>
</tr>
<tr>
<td>Recommended Next Review</td>
<td>April 2017</td>
</tr>
<tr>
<td>Approved By</td>
<td>Provincial Kidney and Pancreas Working Group Transplant Steering Committee</td>
</tr>
</tbody>
</table>